# Sai Parenterals Q2 Net Profit Rises 65% as Revenue Jumps 264% and Board Approves SP Analytics Buyout > Sai Parenterals posted a 65% rise in Q2 net profit to ₹105.10 million on revenue of ₹1,949.18 million. - Published: 2026-11-01T10:12:38+00:00 - Section: Earnings & Results - Author: News Desk - URL: https://newsforagent.com/news/2026-11-01/sai-parenterals-q2-profit-revenue-sp-analytics - Source: [ScanX](https://scanx.trade/stock-market-news/companies/sai-parenterals-q2fy27-results-net-profit-up-65-yoy-105-million/55071223) ## Key takeaways - Sai Parenterals reported consolidated net profit of ₹105.10 million for Q2FY27, up 65% year on year. - Revenue from operations rose 264% to ₹1,949.18 million from ₹535.28 million a year earlier. - The board approved acquiring the remaining 25% of SP Analytics for ₹25,000 across 2,500 equity shares, making it a wholly owned subsidiary. [Sai Parenterals](https://akta.pro/company-profiles/0003fi8/sai-parenterals) reported a 65% year-on-year rise in consolidated net profit to ₹105.10 million for the quarter ended September 30, 2026, with revenue from operations up 264% to ₹1,949.18 million. [ScanX](https://scanx.trade/stock-market-news/companies/sai-parenterals-q2fy27-results-net-profit-up-65-yoy-105-million/55071223) published the results on November 1, 2026. The Hyderabad-based company makes branded generic formulations and runs a CDMO business across injectables, orals and cephalosporins for government agencies, pharmaceutical companies and export markets. ## Sai Parenterals' Revenue and Profit Growth Revenue from operations climbed from ₹535.28 million in the same quarter last year. Total income rose to ₹1,986.37 million from ₹548.63 million, and profit before tax increased to ₹98.89 million from ₹91.54 million. Basic earnings per share rose to ₹2.38 from ₹0.48. Cash and cash equivalents fell to ₹1,293.30 million from ₹4,169.66 million at the start of the half-year. Cash generated from operations was negative at ₹2,012.98 million, which the report attributes mainly to a ₹734.92 million increase in trade receivables and a ₹1,131.41 million decrease in other financial liabilities. ## SP Analytics Stake and Saicriti Pharma Deal The board approved the acquisition of the remaining 25% equity shareholding in SP Analytics Private Limited, a subsidiary in which Sai Parenterals already held 75%. The transaction is valued at ₹25,000 for 2,500 equity shares and will make SP Analytics a wholly owned subsidiary. SP Analytics was incorporated in November 2023 and reported nil turnover over the last three financial years. The board also noted the completion of the acquisition of 60% of the equity share capital of Saicriti Pharma Private Limited, which has become a subsidiary. A Management Committee chaired by Managing Director Anil Kumar Karusala was constituted to oversee administration. ## Sai Parenterals' Listing and Noumed Stake According to akta.pro [company records](https://akta.pro/company-data), Sai Parenterals listed on the NSE and BSE on April 2, 2026 under ticker SAIPARENT (BSE: 544742), with shares debuting at a 2-3% premium to the ₹392 issue price. The company completed its IPO in March 2026, raising ₹408.79 crore through a ₹285 crore fresh issue and a ₹123.79 crore offer for sale. In November 2025 it acquired a 74.6% equity stake in Australian pharmaceutical company Noumed Pharmaceuticals Pty Ltd for ₹125 crore ($13.9 million). ## Australian Contracts Before the Results In August 2026, Sai Parenterals' subsidiary Noumed renewed an OTC supply agreement with an Australian pharmacy chain, raising the contract value to AUD 30 million (₹204 crore) over three years, Business Standard reported. CNBCTV18 reported that a three-year, AU$30 million supply agreement lifted the company's total contracted OTC commitments in Australia to AU$232 million, or about ₹1,506 crore. In July 2026, BusinessLine reported that Noumed renewed an exclusive OTC medicines supply agreement with an Australian pharmacy chain, expanding the portfolio and agreement value to ₹1,300 crore over 7.5 years. ## Sai Parenterals' Investor Meeting Date Sai Parenterals will hold an analyst and institutional investor meeting on October 14, 2026 at 11:00 am at its facilities in Hyderabad, according to a filing signed by Anil Kumar Karusala. ## Companies in this story - [Sai Parenterals company profile](https://akta.pro/company-profiles/0003fi8/sai-parenterals) · website: https://www.saiparenterals.com/home --- News for Agent · https://newsforagent.com/llms.txt